Vizsgálati helyszín
Frankfurt am Main
Frankfurt am Main, Hesse 60590, NémetországMég nincs intézményhez kötve
- 6futó vizsgálat
- 16lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 22 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis8 vizsgálat
- 2. fázis5 vizsgálat
- 4. fázis2 vizsgálat
- 1. fázis1 vizsgálat
- Állapot
- Lezárult14 vizsgálat
- Fut, nem toboroz3 vizsgálat
- Toboroz3 vizsgálat
- Leállították2 vizsgálat
- Fő szponzor
- Novartis Pharmaceuticals22 vizsgálat
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Lezárt vizsgálatok
Lezárult
A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP)
NCT06097663· 2. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Characterizing Guideline Adoption and Treatment Quality in Clinical Routine of German HFrEF Care
NCT06004453· Novartis Pharmaceuticals· Forrás
Lezárult
An Efficacy, Safety, Tolerability and Dose Finding Study of XXB750 in Resistant Hypertension Patients.
NCT05562934· 2. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other Therapies
NCT05566756· Novartis Pharmaceuticals· Forrás
Toboroz
A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
NCT05344469· Novartis Pharmaceuticals· Forrás
Contact: Novartis Pharmaceuticals
Lezárult
Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
NCT05192941· 4. fázis· Novartis Pharmaceuticals· Forrás
Leállították
Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC
NCT04952753· 2. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Asciminib Treatment Optimization in ≥ 3rd Line CML-CP
NCT04948333· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
NCT04679935· 4. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
NCT04543331· Novartis Pharmaceuticals· Forrás
Leállították
Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)
NCT04266301· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
NCT04023552· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
NCT03798626· 1. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
NCT03106779· 3. fázis· Novartis Pharmaceuticals· Forrás
Lezárult
A Non-interventional Study for Women With HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer to Evaluate the Real-world Effectiveness of Treatment Algorithms Beginning With Ribociclib + AI/FUL, or With Endocrine Therapy or Chemotherapy as First Line Treatment
NCT06311383· Novartis Pharmaceuticals· Forrás
Lezárult
Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients
NCT01784068· 2. fázis· Novartis Pharmaceuticals· Forrás
Hibát jelzek